Abstract:Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Drug selection in treatment of patients where the disease is showing resistance to therapy is often guided by IC 50 or fold-IC 50 values. In this work, through a model of the treatment of chronic myeloid leukaemia (CML), we contest using fold-IC 50 values as a guide for treatment selection. CML is a blood cancer that is treated with Abl1 inhibitors, and is often seen as a model for targeted therapy and drug resistance. Resistance to the first-line treatment occurs in approximately one in four patients. The most common cause of resistance is mutations in the Abl1 enzyme. Different mutant Abl1 enzymes show resistance to different Abl1 inhibitors and the mechanisms that lead to resistance for various mutation and inhibitor combinations are not fully known, making the selection of Abl1 inhibitors for treatment a difficult task. We developed a model based on information of catalysis, inhibition and pharmacokinetics, and applied it to study the effect of three Abl1 inhibitors on mutants of the Abl1 enzyme. From this model, we show that the relative decrease of product formation rate (defined in this work as "inhibitory reduction prowess") is a better indicator of resistance than an examination of the size of the product formation rate or fold-IC 50 values for the mutant. We also examine current ideas and practices that guide treatment choice and suggest a new parameter for selecting treatments that could increase the efficacy and thus have a positive impact on patient outcomes. Resistance to drug treatments is a major problem in treating diseases. Choosing the right drug for a patient who shows resistance to treatment is a tricky business. Using a model of the treatment of chronic myeloid leukaemia (CML), we challenge the current methods of using IC50 values to guide treatment selection. CML is a blood cancer that is treated with drugs called Abl1 inhibitors. Around one in four patients will show resistance to the first treatment they are given. The Abl1 inhibitors target the Abl1 enzyme, mutations in this enzyme are the most common cause for drug resistance. Different drugs work better for different mutations, but how this happens is not fully understood, which makes choosing treatment difficult. We developed a model based on how the Abl1 enzyme works, how the inhibitor affects the enzyme, and drug concentrations in patients. The model shows that the relative decrease in the efficacy of the enzyme (which we named "inhibitory reduction prowess") better indicates which drugs should be selected for which mutation than the usual current methods. We also examine other factors that guide treatment choice and suggest a new method for selecting treatments that could have a positive impact on patients.

Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

Dynamics of chronic myeloid leukaemia

Dynamics and bifurcations in a model of chronic myeloid leukemia with optimal immune response windows

Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics

Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy

Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia

High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia

Optimized Treatment Schedules for Chronic Myeloid Leukemia

Beyond IC 50 —A computational dynamic model of drug resistance in enzyme inhibition treatment

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

Beyond IC - A computational dynamic model of drug resistance in enzyme inhibition treatment

Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line

Understanding the impact of feedback regulations on blood cell production and leukemia dynamics using model analysis and simulation of clinically relevant scenarios

Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia

Single Cell Sequencing Reveals Cell Populations That Predict Primary Resistance to Imatinib in Chronic Myeloid Leukemia.